Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer

被引：4

作者：

Ding, Qian ^{[1
]}

Zhan, Jinbiao ^{[1
]}

机构：

[1] Zhejiang Univ, Sch Med, Dept Biochem, Hangzhou 310058, Zhejiang, Peoples R China

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2013年 / 7卷

关键词：

amrubicin; cisplatin; carboplatin; combination therapy; small-cell lung cancer; antibody-drug conjugates; ACTIVE METABOLITE AMRUBICINOL; PREVIOUSLY UNTREATED PATIENTS; COLONY-STIMULATING FACTOR; RANDOMIZED PHASE-II; PHARMACOKINETIC CHARACTERIZATION; SYNTHETIC; 9-AMINOANTHRACYCLINE; C609T POLYMORPHISM; 1ST-LINE TREATMENT; CARDIAC SAFETY; DOXORUBICIN;

D O I：

10.2147/DDDT.S41910

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer characterized by early metastasis and high mortality. In recent years, monotherapy and combination therapy of amrubicin with cisplatin or carboplatin has been actively studied and shown promise for the treatment of extensive disease SCLC (ED-SCLC). In this article, we summarize clinical trials of both monotherapy and combination therapy with amrubicin conducted in Japan, the USA, and the European Union. The results suggest that the clinical outcome of amrubicin therapy may be associated with genetic variations in patients. Further study of combination regimens in patients of different ethnicities is warranted.

引用

页码：681 / 689

页数：9

共 50 条

[1] The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells
Takigawa, N
Takeyama, M
Shibayama, T
Tada, A
Kawata, N
Okada, C
Aoe, K
Kozuki, T
Hotta, K
Tabata, M
Kiura, K
Ueoka, H
Tanimoto, M
Takahashi, K
[J]. ONCOLOGY REPORTS, 2006, 15 (04) : 837 - 842
[2] Small-cell lung cancer responds to amrubicin
Bosch, Xavier
[J]. LANCET ONCOLOGY, 2007, 8 (01): : 13 - 13
[3] Amrubicin for non-small-cell lung cancer and small-cell lung cancer
Kurata, Takayasu
Okamoto, Isamu
Tamura, Kenji
Fukuoka, Masahiro
[J]. INVESTIGATIONAL NEW DRUGS, 2007, 25 (05) : 499 - 504
[4] Amrubicin for non-small-cell lung cancer and small-cell lung cancer
Takayasu Kurata
Isamu Okamoto
Kenji Tamura
Masahiro Fukuoka
[J]. Investigational New Drugs, 2007, 25 : 499 - 504
[5] A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer
Inoue, Akira
Yamazaki, Koichi
Maemondo, Makoto
Suzuki, Takuji
Kimura, Yuichiro
Kanbe, Mariko
Isobe, Hiroshi
Nishimura, Masaharu
Saijo, Yasuo
Nukiwa, Toshihiro
[J]. JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (06) : 551 - 555
[6] Amrubicin hydrochloride for relapsed small-cell lung cancer
Byron, Elizabeth
Chiappori, Alberto
[J]. EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (12): : 1041 - 1047
[7] Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer
Okuma, Hitomi Sumiyoshi
Horinouchi, Hidehito
Kitahara, Shinsuke
Asao, Tetsuhiko
Sunami, Kuniko
Goto, Yasushi
Kanda, Shintaro
Fujiwara, Yutaka
Nokihara, Hiroshi
Yamamoto, Noboru
Ohe, Yuichiro
[J]. CLINICAL LUNG CANCER, 2017, 18 (02) : 234 - +
[8] Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer
Hirose, Takashi
Nakashima, Masanao
Shirai, Takao
Kusumoto, Sojiro
Sugiyama, Tomohide
Yamaoka, Toshimitsu
Okuda, Kentaro
Ohnishi, Tsukasa
Ohmori, Tohru
Adachi, Mitsuru
[J]. LUNG CANCER, 2011, 73 (03) : 345 - 350
[9] Prognosis of small-cell lung cancer since the introduction of amrubicin
Suzuki, Hidekazu
Hirashima, Tomonori
Kobayashi, Masashi
Sasada, Shinji
Okamoto, Norio
Tamiya, Motohiro
Matsuura, Yuka
Morishita, Naoko
Uehara, Nobuko
Matsui, Kaoru
Kawase, Ichiro
[J]. MEDICAL ONCOLOGY, 2011, 28 (04) : 1430 - 1435
[10] CARBOPLATIN IN SMALL-CELL LUNG-CANCER
GATZEMEIER, U
HOSSFELD, DK
NEUHAUSS, R
RECK, M
ACHTERRATH, W
LENAZ, L
[J]. SEMINARS IN ONCOLOGY, 1991, 18 (01) : 8 - 16

← 1 2 3 4 5 →